EBNEO Commentary: Cord Blood Red Cell Transfusions and Severe Retinopathy of Prematurity in Preterm Neonates

Cord blood red cell concentrates for preterm neonate transfusion: Insights from the multicenter BORN trial

“…13 Despite these limitations, the potential clinical benefit of this novel transfusion approach for severe ROP and BPD has attracted significant attention. [17][18][19][20][21] Sharing data on the 451 CB units collected and processed during the BORN study period, along with highlighting the challenges encountered, could help inform the design of future clinical trials exploring this transfusion approach. As stated above, an important issue encountered in the BORN study was the insufficient availability of CB-RBC units for patients in the intervention arm, which was unexpected given that 5467 CB units were collected in the same period at participating CB banks.…”

Cord blood red cell concentrates for preterm neonate transfusion: Insights from the multicenter BORN trial

“…13 Despite these limitations, the potential clinical benefit of this novel transfusion approach for severe ROP and BPD has attracted significant attention. [17][18][19][20][21] Sharing data on the 451 CB units collected and processed during the BORN study period, along with highlighting the challenges encountered, could help inform the design of future clinical trials exploring this transfusion approach. As stated above, an important issue encountered in the BORN study was the insufficient availability of CB-RBC units for patients in the intervention arm, which was unexpected given that 5467 CB units were collected in the same period at participating CB banks.…”

Cord blood red cell concentrates for preterm neonate transfusion: Insights from the multicenter BORN trial

“…13 Despite these limitations, the potential clinical benefit of this novel transfusion approach for severe ROP and BPD has attracted significant attention. [17][18][19][20][21] Sharing data on the 451 CB units collected and processed during the BORN study period, along with highlighting the challenges encountered, could help inform the design of future clinical trials exploring this transfusion approach. As stated above, an important issue encountered in the BORN study was the insufficient availability of CB-RBC units for patients in the intervention arm, which was unexpected given that 5467 CB units were collected in the same period at participating CB banks.…”

Cord blood red cell concentrates for preterm neonate transfusion: Insights from the multicenter BORN trial

“…13 Despite these limitations, the potential clinical benefit of this novel transfusion approach for severe ROP and BPD has attracted significant attention. [17][18][19][20][21] Sharing data on the 451 CB units collected and processed during the BORN study period, along with highlighting the challenges encountered, could help inform the design of future clinical trials exploring this transfusion approach. As stated above, an important issue encountered in the BORN study was the insufficient availability of CB-RBC units for patients in the intervention arm, which was unexpected given that 5467 CB units were collected in the same period at participating CB banks.…”